Management of advanced parotid cancer. A systematic review

Eur J Surg Oncol. 2009 Sep;35(9):908-15. doi: 10.1016/j.ejso.2008.10.009. Epub 2008 Nov 21.

Abstract

Background: Primary adenocarcinomas of the parotid gland are rare and account for less than 5% of all head and neck malignant neoplasms. There is considerable variation in biological behaviour within this group; low-grade tumours exhibit slow growth rates with minimal or no local invasion. High-grade tumours, however, show a high incidence of local recurrence and distant metastasis.

Aim: The purpose of this paper is to analyse the important prognostic indicators for this cancer.

Methods: A systematic review was performed involving 19 published studies from 1987 to 2005 which included 4631 patients. T stage, grade of tumour, N stage and adjuvant radiotherapy on overall (5 year) survival were analysed as prognostic indicators.

Results: T stage (p=0.041, hazard ratio 1.8 (confidence interval 1.2-2.9)), N stage (p=0.05, hazard ratio 1.1 (0.2-1.8)), and high-grade (p=0.001, hazard ratio 2.1 (1.5-2.7)) were associated with a significantly worse survival. The effect of adjuvant radiotherapy was to improve overall survival: p=0.002, hazard ratio 2.9 (1.5-4.7). The mean 5 year survival for advanced high-grade parotid cancer was 35%.

Conclusion: High-grade advanced parotid cancers are associated with a poor survival. Adjuvant radiotherapy is indicated in these tumours and this improves survival.

Publication types

  • Comparative Study
  • Review
  • Systematic Review

MeSH terms

  • Adenocarcinoma / pathology*
  • Adenocarcinoma / surgery
  • Adenocarcinoma / therapy*
  • Humans
  • Neoplasm Staging
  • Parotid Neoplasms / pathology*
  • Parotid Neoplasms / surgery
  • Parotid Neoplasms / therapy*
  • Prognosis
  • Radiotherapy, Adjuvant
  • Survival Analysis
  • Treatment Outcome